nach oben

European Journal of Medical Research

Erschienen in:

01.12.2011 | Review

Pharmacology and metabolism of voriconazole and posaconazole in the treatment of invasive aspergillosis-review of the literature

verfasst von: M Sandherr, G Maschmeyer

Erschienen in: European Journal of Medical Research | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Invasive fungal infections, predominantly aspergillosis and candidiasis, are among the most important causes of morbidity and mortality in immunocompromised patients. Primarily, patients with acute leukemia undergoing myelosuppressive chemotherapy and allogeneic stem cell transplant recipients are affected. Up to 60% of patients with invasive aspergillosis, the most common invasive mycosis among patients with hematologic malignancies, may still die of their infection, once it has become clinically overt. The spectrum of antifungal agents for clinical use now has expanded over the past ten years and includes the novel class of the echinocandins and two newer generation triazoles with an extended spectrum of activity against a wide range of fungal pathogens. This review will address pharmacological characteristics of the two broad-spectrum antifungal azoles, voriconazole and Posaconazole, which are important for their proper use in clinical practice.

Marr KA, Carter RA, Crippa F, et al.: Epidemiology and outcome of mould infections in haematopoietic stem cell recipients. Clin Infect Dis 2002, 34: 909–17. 10.1086/339202PubMedCrossRef

Pagano L, Caira M, Candoni A, et al.: The epidemiology of fungal infections in patients with hematological malignancies: the SEIFEM-2004 study. Haematologica 2006, 91: 1068–75.PubMed

Cuenca-Estrella M, Bernal-Martinez I, Buitrago MJ, et al.: Update on the epidemiology and diagnosis of invasive fungal infections. Int J Antimicrob Agents 2008,32(suppl2):S143–7.PubMedCrossRef

Patterson TF: Advances and challenges in management of invasive mycosis. Lancet 2005, 366: 1013–25. 10.1016/S0140-6736(05)67381-3PubMedCrossRef

Steinbach WJ, Stevens DA: Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis 2003,37(suppl3):S157–87.PubMedCrossRef

Verweij PE, Mellado E, Melchers WJ: Multiple-triazole-resistant aspergillosis. N Engl J Med 2007, 356: 1481–3.PubMedCrossRef

Boucher HW, Groll AH, Chiou CC, et al.: Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 2004, 64: 1997–20. 10.2165/00003495-200464180-00001PubMedCrossRef

Purkins L, Wood N, Greenhalgh K, et al.: Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol 2003, 56: Suppl 1:10–6.

Purkins L, Wood N, Kleinermans D, Greenhalgh K, et al.: Effect of food on the pharmacokinetics of multiple-dose oral Voriconazole. Br J Clin Pharmacol 2003, 56: 17–23.PubMedCentralPubMedCrossRef

10.

Purkins L, Wood N, Ghahramani P, et al.: Pharmacokinetics and safety of Voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002, 46: 2546–53. 10.1128/AAC.46.8.2546-2553.2002PubMedCentralPubMedCrossRef

11.

Hyland R, Jones BC, Smith DA: Identification of the cytochrome P450 enzymes involved in the N-oxidation of Voriconazole. Drug Metab Dispos 2003, 31: 540–7. 10.1124/dmd.31.5.540PubMedCrossRef

12.

Miyakis S, van Hal SJ, Ray J, et al.: Voriconazole concentrations and outcome of invasive fungal infections. Clin Infect Dis 2010, 16: 927–33.CrossRef

13.

Bruggemann RJ, Blijlevens NM, Burger DM, et al.: Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients. J Antimicrob Chemother 2010, 65: 107–13. 10.1093/jac/dkp416PubMedCrossRef

14.

Denning DW, Ribaud P, Milpied N, et al.: Efficacy and safety of voriconazol in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002, 34: 563–71. 10.1086/324620PubMedCrossRef

15.

Trifilio S, Pennick G, Pi J, et al.: Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in haematopoietic stem cell recipients. Cancer 2007, 109: 1532–5. 10.1002/cncr.22568PubMedCrossRef

16.

Craig WA, Suh B: Protein binding and the antimicrobial effects: methods for determination of protein binding. In Antibiotics in laboratory medicine. Edited by: Lorian V. Philadelphia (PA): Lippincott Williams & Wilkins; 1991:367–402.

17.

Jeu L, Piacenti FJ, Lyakhovetskiy AG, et al.: Voriconazole. Clin Ther 2003, 25: 1321–81. 10.1016/S0149-2918(03)80126-1PubMedCrossRef

18.

Ikeda Y, Umemura K, Kondo K, et al.: Pharmacokinetics of Voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther 2004, 75: 587–8. 10.1016/j.clpt.2004.02.002PubMedCrossRef

19.

Pfizer Inc: Label: Voriconazole for injections, tablets, oral suspension: LAB -0271–12. 2005.

20.

Drago M, Scaltrito MM, Morace G: In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei. Eur J Clin Microbiol Infect Dis 2004, 23: 619–24.PubMedCrossRef

21.

Gil-Lamaignere C, Hess R, Salvenmoser S: Effect of media composition and in vitro activity of Posaconazole, Caspofungin and Voriconazole against zygomycetes. J Antimi-crob Chemother 2005, 55: 1016–9. 10.1093/jac/dki140CrossRef

22.

Walsh TJ, Anaissie EL, Denning DW, et al.: Treatment of Aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008, 46: 327–60. 10.1086/525258PubMedCrossRef

23.

Herbrecht R, Denning DW, Patterson TF, et al.: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347: 408–15. 10.1056/NEJMoa020191PubMedCrossRef

24.

Wingard JL, Carter SL, Walsh TJ, et al.: Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic haematopoietic cell transplantation. Blood 2010, 116: 5111–18. 10.1182/blood-2010-02-268151PubMedCentralPubMedCrossRef

25.

Smith JA: What is the role of therapeutic drug monitoring in antifungal therapy? Curr Infect Dis Rep 2009, 11: 439–46. 10.1007/s11908-009-0064-9PubMedCrossRef

26.

Nagappan V, Deresinski S: Posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 2007, 45: 1610–7. 10.1086/523576PubMedCrossRef

27.

Li Y, Theuretzbacher U, Clancy CJ, et al.: Pharmacokinetic/Pharmacodynamic profile of Posaconazole. Clin Pharmacokinet 2010, 49: 379–96. 10.2165/11319340-000000000-00000PubMedCrossRef

28.

Courtney R, Pai S, Laughlin M, et al.: Pharmacokinetics, safety, and tolerability of oral Posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003, 47: 2788–95. 10.1128/AAC.47.9.2788-2795.2003PubMedCentralPubMedCrossRef

29.

Ezzet F, Wexler D, Courtney R, et al.: Oral bioavailability of Posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005, 44: 211–20. 10.2165/00003088-200544020-00006PubMedCrossRef

30.

Schering-Plough Inc: Label: Noxafil^® (Posaconazole) oral suspension. Labeling - 31029708. Kenilworth (NJ): Schering-Plough Inc.; 2006.

31.

Wexler D, Courtney R, Richards W, et al.: Effect of Posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004, 21: 645–53. 10.1016/j.ejps.2004.01.005PubMedCrossRef

32.

Ghosal A, Hapangama N, Yuan Y, et al.: Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil^® ). Drug Metab Dispos 2004, 32: 267–71. 10.1124/dmd.32.2.267PubMedCrossRef

33.

Courtney R, Wexler D, Radwanski E, et al.: Effect of food on the relative bioavailability of two oral formulations of Posaconazole in healthy adults. Br J Clin Pharmacol 2004, 57: 218–22.PubMedCentralPubMedCrossRef

34.

Courtney R, Radwanski E, Lim J, et al.: Pharmacokinetics of Posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother 2004, 48: 804–8. 10.1128/AAC.48.3.804-808.2004PubMedCentralPubMedCrossRef

35.

Ullmann A, Lipton J, Vesole D, et al.: Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007, 356: 335–47. 10.1056/NEJMoa061098PubMedCrossRef

36.

Cornely OA, Maertens J, Winston D, et al.: Posaconazole vs fluconazole or itraconazole prophylaxis for patients with neutropenia. N Engl J Med 2007, 356: 348–359. 10.1056/NEJMoa061094PubMedCrossRef

37.

De Pauw BE, Donnelly JP: Prophylaxis and aspergillosis - has the principle been proven? N Engl J Med 2007, 356: 409–11. 10.1056/NEJMe068266PubMedCrossRef

38.

van Burik JAH, Hare RS, Solomon HF, et al.: Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006, 42: e61–5. 10.1086/500212PubMedCrossRef

39.

Walsh TJ, Raad I, Patterson TF, et al.: Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trail. Clin Infect Dis 2007, 44: 2–12. 10.1086/508774PubMedCrossRef

Titel: Pharmacology and metabolism of voriconazole and posaconazole in the treatment of invasive aspergillosis-review of the literature
verfasst von: M Sandherr
G Maschmeyer
Publikationsdatum: 01.12.2011
Verlag: BioMed Central
Erschienen in: European Journal of Medical Research / Ausgabe 4/2011
Elektronische ISSN: 2047-783X
DOI: https://doi.org/10.1186/2047-783X-16-4-139

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2011

Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin - review of the literature

Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis - review of the literature

Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs - review of the literature

Epidemiology and antifungal resistance in invasive candidiasis

Epidemiology and antifungal resistance in invasive aspergillosis according to primary disease - review of the literature

Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin - review of the literature